Show simple item record

dc.contributor.authorRamchandren, R*
dc.contributor.authorJohnson, P*
dc.contributor.authorGhosh, N*
dc.contributor.authorRuan, J*
dc.contributor.authorArdeshna, M*
dc.contributor.authorJohnson, R*
dc.contributor.authorVerhoef, G*
dc.contributor.authorCunningham, D*
dc.contributor.authorde Vos, S*
dc.contributor.authorKassam, S*
dc.contributor.authorFayad, L*
dc.contributor.authorRadford, John A*
dc.contributor.authorBailly, S*
dc.contributor.authorOffner, F*
dc.contributor.authorMorgan, D*
dc.contributor.authorMunoz, J*
dc.contributor.authorPing, J*
dc.contributor.authorCo, M*
dc.contributor.authorNeuenburg, K*
dc.contributor.authorGoy, A*
dc.date.accessioned2019-03-29T14:22:31Z
dc.date.available2019-03-29T14:22:31Z
dc.date.issued2018en
dc.identifier.citationRamchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna K, Johnson R, et al. The iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma. Blood. 2018;132.en
dc.identifier.doi10.1182/blood-2018-99-111163en
dc.identifier.urihttp://hdl.handle.net/10541/621670
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2018-99-111163en
dc.titleThe iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCase Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OHen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record